• Explore /
  • Poster
  • / Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study.

Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study.

Abstract Poster

Authors

null

Kana Miyazaki

Mie University Graduate School of Medicine, Tsu, Japan

Kana Miyazaki , Naoko Asano , Tomomi Yamada , Kohta Miyawaki , Hirotaka Takasaki , Tadahiko Igarashi , Momoko Nishikori , Kinya Ohata , Kazutaka Sunami , Isao Yoshida , Yuki Nishimura , Satoshi Tamaru , Masakatsu Nishikawa , Koji Izutsu , Tomohiro Kinoshita , Junji Suzumiya , Koichi Ohshima , Koji Kato , Naoyuki Katayama , Motoko Yamaguchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

UMIN000008507

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7561)

DOI

10.1200/JCO.2018.36.15_suppl.7561

Abstract #

7561

Poster Bd #

198

Abstract Disclosures

Similar Posters

First Author: Laurie Helen Sehn

First Author: Kana Miyazaki

Poster

2023 ASCO Annual Meeting

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

First Author: Carrie Ho

First Author: Hua-Jay Jeffery Cherng